Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy  by Goodman, Shaun G et al.
Low Molecular Weight Heparin Decreases
Rebound Ischemia in Unstable Angina
or Non-Q-Wave Myocardial Infarction: The
Canadian ESSENCE ST Segment Monitoring Substudy
Shaun G. Goodman, MD, FACC,* Aiala Barr, PHD,* Anatoli Sobtchouk, MD,*
Marc Cohen, MD, FACC,† Gregg J. Fromell, MD,‡ Luc Laperrie`re, MD,§ Carol Hill, RN,*
Anatoly Langer, MD, FACC,* for the Canadian Efficacy and Safety of Subcutaneous Enoxaparin in
Non-Q-Wave Coronary Events (ESSENCE) ST Segment Monitoring Substudy Group
Toronto and Montreal, Canada; Philadelphia, Pennsylvania; and Princeton, New Jersey
OBJECTIVES The goal of this study was to determine whether enoxaparin was more effective than heparin
in reducing recurrent ischemic episodes.
BACKGROUND Continuous ST segment monitoring is a simple tool for assessment of ischemia and identifies
patients with a worse prognosis. Little is known about the impact of low molecular weight
heparin on ST segment shift.
METHODS Patients were randomized to receive enoxaparin or heparin (mean 3.4 days). Three-lead ST
segment monitoring was performed for the first 48 h (n 5 220) and an additional 48 h (n 5
174) after intravenous study drug discontinuation (mean 1.9 days later).
RESULTS During initial monitoring, ischemia rates were similar among the heparin and enoxaparin
groups (27.2% vs. 22.6%, p 5 0.44); however, the time to first ischemic episode was earlier
among heparin-treated patients (11 6 11 vs. 25 6 18 min, p 5 0.001). After drug
discontinuation, ischemic episodes occurred more frequently (44.6% vs. 25.6%, p 5 0.009),
and the total ischemic duration was greater among heparin patients (18 6 39 vs. 5 6
12 min/24 h, p 5 0.005). Recurrent ischemia occurred more frequently after discontinuation
in the heparin (46% vs. 31%, p 5 0.043), but not the enoxaparin, group (18.4% vs. 25%, p 5
0.33). Regardless of treatment, patients with ischemia were more likely to die or experience
(re)infarction at one year (18.4% vs. 8.3%, p 5 0.023).
CONCLUSIONS ST segment shift occurs frequently in unstable angina/non-Q-wave myocardial infarction
despite antithrombotic therapy and is associated with worse one-year prognosis. Enoxaparin
is a more effective antithrombotic treatment than unfractionated heparin and leads to greater
prevention of rebound ischemia. (J Am Coll Cardiol 2000;36:1507–13) © 2000 by the
American College of Cardiology
Continuous ST segment monitoring is an effective and
simple tool for assessment of ongoing or recurrent ischemia.
Patients with unstable angina or non-Q-wave myocardial
infarction (MI) who experience episodic ST segment
shifts—mostly silent—have worse short- (1–10) and long-
term (7,11,12) prognosis. Further, the prognostic value of
ST segment shifts during continuous monitoring has been
demonstrated in addition to other important variables, such
as left ventricular function or angiographic extent of coro-
nary artery disease (4,13).
Cycles of thrombosis and thrombolysis appear to
mediate ischemic ST segment shifts in patients with
acute coronary syndromes (14). However, despite anti-
platelet and antithrombotic treatment, transient myocar-
dial ischemia as detected by continuous electrocardio-
graphic (ECG) monitoring occurs in 15% to 40% of
patients with unstable angina or non-Q-wave MI
(9,10,15).
We have previously reported a significant benefit of
enoxaparin (a low molecular weight heparin [LMWH])
compared with unfractionated heparin (UFH) on the back-
ground of aspirin therapy in the 14-day incidence of death,
MI or patients with recurrent angina with unstable angina
or non-Q-wave MI (16). The purpose of this study was to
determine whether enoxaparin was more effective in reduc-
ing recurrent ischemic episodes in patients with unstable
angina or non-Q-wave MI. Specifically, the following three
hypotheses were prospectively identified: 1) treatment with
enoxaparin as compared with UFH will result in a signifi-
cant reduction in the incidence of recurrent ischemia during
the first 48 h; 2) patients treated with enoxaparin as
compared with UFH will have fewer ischemic episodes
during the 48 h after study drug discontinuation; and 3)
regardless of study drug treatment, patients with, as com-
pared with those without, ST segment shift during the first
48 h or during the 48 h after treatment discontinuation will
have a higher death or nonfatal (re)infarction rate.
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METHODS
Patient population and treatment. The entry criteria for
enrollment, study design and treatment protocol and end
point definitions in the Efficacy and Safety of Subcutaneous
Enoxaparin in Non-Q-Wave Coronary Events (ES-
SENCE) study have been described in detail (16). Briefly,
3,171 patients with rest angina occurring within 24 h and
evidence of underlying ischemic heart disease (manifested
by new ECG changes or previously documented coronary
disease) were randomized to receive (double-blind, double-
dummy) enoxaparin (Rhone-Poulenc Rorer, Collegeville,
Pennsylvania) or UFH for a minimum of 48 h. All patients
received 100 to 325 mg of oral aspirin daily. All other
medications, the decision to proceed with cardiac catheter-
ization and the use of coronary revascularization were left to
the discretion of the investigator.
Patients participating in the main study from 20 Cana-
dian sites were also approached to participate in the ST
segment monitoring substudy from September 15, 1995 to
the end of the main trial in May 1996 (Fig. 1). Written,
informed consent was obtained from all patients, and the
study was approved by the institutional review board of each
participating hospital.
ST segment monitoring. Three-channel (leads aVF, V2,
V5) ST segment monitoring (Marquette Electronics, Mil-
waukee, Wisconsin) was performed on patients for the first
48 h after randomization and for an additional 48 h after
intravenous study drug discontinuation. Analysis was per-
formed initially by using an automated algorithm with all
potential episodes of transient ST segment shift printed on
paper. Data were subsequently reviewed by three cardiolo-
gists who were blinded to the clinical data and treatment
assignment. The ST segment was measured 80 ms after the
J point. Significant ST segment shift was defined as hori-
zontal or downsloping ST depression $0.1 mV below the
baseline or upward ST elevation $0.1 mV above the
baseline lasting $1 min in duration and separated from
other episodes of ST segment shift by $1 min. Patients
with ST segment changes at baseline attributed to left
ventricular hypertrophy with repolarization changes, bundle
branch block and digoxin were excluded. In those patients
with ST segment depression at baseline of 0.1 mV, a further
depression of 0.15 mV (0.25 mV absolute) was required;
similarly, baseline depression of 0.15 mV and 0.2 mV
required further depression of 0.2 mV (0.35 absolute) and
0.3 mV (0.50 absolute), respectively, for qualification of an
ischemic episode. Patients with .0.25 mV baseline ST
depression were excluded. A similar approach was adopted
for ST segment elevation episodes.
Clinical follow-up. The primary clinical outcome was the
composite double end point of death or nonfatal myocardial
(re)infarction at one year. One-year follow-up was obtained
in a retrospective manner and was verified independently by
an end point committee consisting of three cardiologists
unaware of treatment assignment. Death was defined as any
death, regardless of cause. Myocardial infarction, including
periprocedural, was defined as previously reported (16).
Statistical analysis. Descriptive statistics (percentages for
discrete variables, means with standard deviation or medians
with 25th and 75th percentiles for continuous variables)
were calculated for baseline characteristics, ECG and clin-
ical outcomes. Comparison of baseline characteristics and
clinical outcomes between patient groups was carried out
using likelihood-ratio chi-square or Fisher exact test for
differences in proportions of categorical variables and Wil-
coxon rank-sum tests for differences in median values of
continuous variables. Kaplan-Meier estimates were used to
obtain event-free rates at one year, and a curve comparison
was made using the log-rank test. Backward elimination
logistic regression was utilized for prediction of one-year
death or myocardial (re)infarction. Variables considered in
the backward selection were: age, gender, body mass index,
diabetes, diastolic blood pressure, smoking status (current
and former), previous stroke, ST segment deviation on the
baseline ECG, index MI and study drug treatment (enox-
aparin or UFH).
The number and total duration of ischemic episodes were
normalized by the duration of continuous ECG monitoring,
and comparisons between treatments at the initial (first
48 h) and follow-up (48 h after study drug discontinuation)
Abbreviations and Acronyms
CI 5 confidence interval
ECG 5 electrocardiograph
ESSENCE 5 Efficacy and Safety of Subcutaneous
Enoxaparin in Non-Q-Wave Coronary
Events
LMWH 5 low molecular weight heparin
MI 5 myocardial infarction
OR 5 odds ratio
UFH 5 unfractionated heparin
Figure 1. Flowchart showing disposition of patients.
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monitoring periods were made using the Wilcoxon non-
parametric sign test.
RESULTS
Patient participation. Figure 1 shows the flow of patients
through the ST segment monitoring substudy. Two hun-
dred and eighty-eight of 439 patients (66% of all potentially
eligible patients) from 20 Canadian sites participating in the
substudy were enrolled. Fifty-five patients (30 in the UFH
and 25 in the enoxaparin group) were excluded due to
confounding ECG factors or due to significant artifact on
continuous ECG recording. Two hundred and twenty
patients (114 in the heparin and 106 in the enoxaparin
group) underwent initial 48-h monitoring at the time of
study drug initiation, and 174 patients (92 heparin, 82
enoxaparin) underwent follow-up 48-h monitoring begin-
ning at the time of study drug discontinuation. One
hundred and sixty-three patients had ECG recordings
during both monitoring periods (87 heparin, 76 enoxapa-
rin), with a similar time interval between the two ECG
recordings (mean 1.9 6 1.8 and 1.9 6 3.7 days) in both
treatment groups. Study drug treatment duration was 3.3 6
1.7 and 3.5 6 1.8 days in the heparin and enoxaparin
groups, respectively.
ST segment monitoring. During 18,721 h of monitoring
(64 6 24 h/patient), 87 patients (37.1%) had at least one
episode of transient ischemia. Transient ischemic episodes
with ST segment elevation occurred in 21 patients (9.1%).
The rates of ischemia according to baseline ECG ST
segment depression are presented in Table 1.
There were no significant baseline differences between
the two treatment groups (Table 2). The use of beta-
adrenergic blocking agents (77% vs. 72%, p 5 0.3), calcium
blockers (54% vs. 63%, p 5 0.2) and nitrates (85% vs. 81%,
p 5 0.5) was comparable between the UFH and enoxaparin
groups. The mean number, ST segment magnitude, dura-
tion and cumulative duration of ischemic episodes was
6.8 6 8.0 and 3.3 6 3.3 episodes, 20.17 6 0.9 and 21.6 6
0.6 mV, 14.3 6 18.2 and 10.4 6 1.32 min and 98.2 6 143.6
and 34.8 6 56.7 min in the UFH and enoxaparin groups,
respectively. The heart rate preceding and at the onset of ST
segment depression was 70 6 24 and 77 6 25 beats/min
and 67 6 17 and 74 6 16 beats/min in the UFH and
enoxaparin groups, respectively; 63% of UFH and 77% of
enoxaparin-treated patients experienced a less than 10%
increase in heart rate at the onset of ischemia.
The mean duration from the onset of the index episode of
chest discomfort to initiation of ST segment monitoring
and from study randomization to initiation of ST segment
monitoring was similar among the two treatment groups
(heparin 9.1 6 8.5 h and enoxaparin 10.0 6 9.8 h; and
heparin 1.9 6 4.1 h and enoxaparin 2.7 6 7.1 h, respec-
tively).
Initial 48-h ECG monitoring. Among those undergoing
initial 48-h ST segment monitoring (n 5 220, mean 6
standard deviation 37 6 15 h/patient), 31 of 114 (27.2%)
heparin-treated patients and 24 of 106 (22.6%) enoxaparin-
treated patients experienced at least one ischemic episode
(p 5 0.44). However, there was a shorter time to the first
episode of ischemia after study drug initiation among
heparin- as compared with enoxaparin-treated patients
(11.3 6 10.5 vs. 25.4 6 18.3 min, p 5 0.001). After
adjustment for the overall duration of monitoring, the mean
Table 1. Rates of ST Segment Shift According to
Baseline ECG
Baseline ECG ST
Segment Depression
ST Segment Shift
During Continuous
ECG Monitoring
0 to ,0.1 mV 32/105 (30.5%)
0.1 mV to 0.15 mV 20/38 (52.6%)
.0.15 mV to 0.2 mV 1/1 (100%)
.0.2 mV to 0.25 mV 8/14 (57.1%)
ECG 5 electrocardiogram.
Table 2. Patient Characteristics*
Patient Characteristic
Heparin
(n 5 119)
Enoxaparin
(n 5 112) p Value
Age (yr) 64 (56, 73) 67 (56, 74) 0.66
Gender (% male) 58 55 0.69
Race (% white) 91 87 0.31
Height (cm) 167 (161, 176) 165 (158,174) 0.37
Weight (kg) 77 (70, 89) 77 (66, 87) 0.45
History of:
Myocardial infarction (%) 46 53 0.33
Angina (%) 78 77 0.8
Hypertension (%) 49 53 0.55
Diabetes mellitus (%) 23 24 0.8
Hypercholesterolemia (%) 46 45 0.81
Cerebrovascular disease (%) 6 5 0.86
Smoking (%) 56 56 0.4
Heart rate (beats/min) 71 (62, 84) 76 (64,88) 0.11
Systolic blood pressure (mm Hg) 140 (122, 160) 140 (124, 160) 0.52
Diastolic blood pressure (mm Hg) 80 (70, 90) 80 (71, 90) 0.68
*Continuous variables are expressed as median (25th percentile, 75th percentile).
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number of episodes and the adjusted total duration of epi-
sodes per 24 h was similar among heparin- and enoxaparin-
treated patients (0.8 6 2.0 vs. 0.3 6 0.9 episodes/24 h, p 5
0.41 and 12.0 6 34.8 vs. 5.1 6 17.0 min of ischemia/24 h,
p 5 0.35, respectively).
Study drug discontinuation 48 h ECG monitoring. Dur-
ing follow-up 48-h ST segment monitoring (n 5 174, 27 6
19 h/patient), 41 of 92 (44.6%) patients receiving heparin
and 21 of 82 (25.6%) patients treated with enoxaparin
experienced at least one ischemic episode (p 5 0.009). The
time to first ischemic episode after study drug discontinua-
tion was shorter in the heparin group (13.9 6 23.3 vs.
23.8 6 21.1 min, p 5 0.03). The mean number of episodes
and episode duration was greater among patients treated
with heparin (1.5 6 3.0 vs. 0.4 6 0.9 episodes/24 h, p 5
0.005 and 18.0 6 39.2 vs. 4.6 6 12.4 min of ischemia/24 h,
p 5 0.005, respectively).
Paired initial and study drug discontinuation 48-h ECG
monitoring. Among the 163 patients who underwent both
initial and study drug discontinuation monitoring, ischemia
was detected more frequently after the time of study drug
discontinuation (41 [25.2%] initial vs. 59 [36.2%] follow-
up). Ischemia was more frequently observed during both
monitoring periods among the heparin as compared with
the enoxaparin group (28 [32.2%] vs. 14 [18.4%], p 5 0.045
and 40 [46.0%] vs. 19 [25.0%], p 5 0.005, respectively).
There was a shorter time to the first ischemic episode after
study drug initiation among heparin-treated patients
(12.3 6 10.6 vs. 27.8 6 17.8 min, p 5 0.004). After study
drug discontinuation there were a significantly greater
number of heparin-treated patients with ischemia when
compared with the initial monitoring period (46.0% vs.
31.0%, p 5 0.043); in contrast, no increase was seen among
the enoxaparin group (18.4% vs. 25.0%, p 5 0.33). After
adjusting for the duration of monitoring, there were a greater
number of episodes and a trend towards greater episode
duration compared with the initial monitoring period
among heparin (1.6 6 3.0 vs. 0.9 6 2.1 episodes/24 h, p 5
0.04 and 19.0 6 40.1 vs. 14.5 6 38.4 min, p 5 0.06),
but not enoxaparin, treated patients (0.4 6 1.0 vs. 0.2 6
0.6 episodes/24 h, p 5 0.23 and 4.7 6 12.8 vs. 3.7 6
12.4 min of ischemia/24 h, p 5 0.3).
One-year death or MI. Death or nonfatal (re)infarction
occurred in 28 of 221 patients (12.7%); this one-year event
rate was similar to that observed in the overall ESSENCE
trial (12.1% in 3,171 patients). Regardless of study drug
treatment, there was a trend towards higher rates of death or
nonfatal MI (10 of 54 patients [18.5%] vs. 16 of 166
patients [9.6%], p 5 0.079) or death alone (13.0% vs. 4.8%,
p 5 0.058) among patients with, as compared with those
without, ST segment shift during initial monitoring. Pa-
tients with ischemia identified after study drug discontinu-
ation were at higher risk for one-year death or infarction (13
of 62 patients [21.0%] vs. 11 of 112 patients [9.8%], p 5
0.041) but not for mortality alone (8.1% vs. 6.3%, p 5 0.8).
ST segment shift occurring during either 48-h period of
continuous ECG monitoring was associated with a higher
one-year death or infarction rate (16 of 87 patients [18.4%]
vs. 12 of 144 patients [8.3%], p 5 0.023; Fig. 2).
One-year rates of diagnostic cardiac catheterization and
coronary revascularization were similar among the heparin
and enoxaparin groups (40.5% vs. 40.0%, p 5 0.91 and
28.4% vs. 23.7%, p 5 0.52, respectively). After adjustment
for differences in baseline characteristics and other prognos-
tic determinants of outcome in a multivariable model, the
presence of ST segment shift during continuous monitoring
was an important predictor of one-year mortality or (re)in-
farction (double end point). In addition to older age (odds
ratio [OR] 2.1, 95% confidence intervals [CI] 1.3, 3.2) and
history of diabetes mellitus (OR 3.3, 95% CI 1.3, 8.0), the
following interactions were independent predictors of out-
come: ST shift on baseline 12-lead ECG to ST shift on
continuous monitoring (OR 4.5, 95% CI 1.7, 11.8) and
study drug treatment to ST shift on continuous monitoring
(OR 4.7, 95% CI 1.1, 20.4). This suggests that the
predictive value of ST shift on the double end point is
different depending upon whether the patient: 1) had ST
shift on the prerandomization 12-lead ECG, or 2) received
enoxaparin or UFH. As seen in Figure 3, the event rate is
highest in the group that received heparin and had ST shift
on continuous monitoring (25%, p 5 0.0114). In contrast,
Figure 2. Kaplan-Meier plot of 1-year event-free survival from death or
nonfatal myocardial (re)infarction among patients with (solid line, n 5 87)
and without (dashed line, n 5 144) ST segment change (ischemia) during
either initial or study drug discontinuation monitoring.
Figure 3. Kaplan-Meier plot of 1-year event-free survival from death or
nonfatal myocardial (re)infarction among heparin patients (solid lines): 1)
with ST segment change (ischemia) during continuous monitoring (heavy
solid line, n 5 52) and 2) without ischemia during continuous monitoring
(light solid line, n 5 67) and among enoxaparin patients (dashed lines):
1) with ischemia (heavy dashed line, n 5 35) and 2) without ischemia
(light dashed line, n 5 77).
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the enoxaparin-treated subgroup with ischemia detected
during continuous monitoring had a similar one-year
death/MI rate (8.6%) to those heparin and enoxaparin
subgroups without ST shift (9% and 7.8%, respectively). As
seen in Figure 4, the event rate is highest among those
patients with ST shift on both the baseline 12-lead ECG
and during subsequent continuous monitoring (27%, p 5
0.0058), with similar one-year event rates seen among the
other subgroups.
DISCUSSION
In this substudy of patients with unstable angina or non-
Q-wave MI, the rates of recurrent ischemic episodes were
similar among the enoxaparin and UFH groups during the
first 48 h of treatment. However, the time to first ischemic
episode was delayed, and the frequency and duration of
episodes was lower among enoxaparin-treated patients. In
addition, enoxaparin was more effective in preventing isch-
emic rebound during the 48 h after drug discontinuation.
Regardless of study drug treatment, patients with, as com-
pared with those without, ST segment shift during the first
48 h and after drug discontinuation had higher rates of
death or MI at one year.
Comparison with previous studies. ST segment shift in
patients with unstable angina has been previously shown to
portend worse long-term prognosis (7,11,12). For example,
Patel et al. (12) described adverse outcome among 32 of 212
(15.1%) patients with unstable angina with ischemia de-
tected during continuous ST segment monitoring. Medical
therapy included randomized intravenous UFH in half of
the patients, in addition to ASA, beta- and calcium-channel
blockade and intravenous nitroglycerin. Over a median of
2.6 years (range 5 days to 4 years), those with ST shift
during the first 48 h were more likely to have subsequent
death or MI (31.3% vs. 9.4%, p 5 0.0001). However, in the
initial 285 patient report (17), there were no differences in
the rates, number of episodes or total duration of ST shift
during the first 48 h among those treated with or without
heparin. In this study all patients received a heparin prep-
aration in addition to ASA, beta- or calcium-channel
blockade and nitrates. Thus, even in an era of combination
antiplatelet and short-term anticoagulant therapy, transient
myocardial ischemia as detected by continuous ECG mon-
itoring is associated with worse long-term prognosis.
In a randomized, single-blind comparison involving 219
patients, Gurfinkel et al. (15) showed a trend towards lower
rates of silent ischemia ($2 mm of ST segment shift) during
48 h of continuous ECG monitoring with LMWH (na-
droparin) plus aspirin compared with aspirin alone (25% vs.
38%, p 5 0.1); nadroparin was found to be superior to UFH
plus aspirin in the reduction of silent ischemic episodes
(25% vs. 41%, p 5 0.04).
In this analysis, the rates of ST segment shift were not
significantly different in the two treatment groups (5%
absolute difference in favor of enoxaparin). However, with
approximately 110 patients in each group, the power to
detect a moderate (for example, 10% absolute, 30% relative)
reduction was less than 30%. Nonetheless, the time to first
ischemic episode was longer and the frequency and duration
of episodes was lower among enoxaparin- as compared with
heparin-treated patients, suggesting some additional degree
of anti-ischemic benefit with enoxaparin. This benefit was
evident clinically in the overall ESSENCE population
where a 16% relative risk reduction in the composite end
point of recurrent angina, MI or death was seen with
enoxaparin by 48 h (16).
Rebound ischemia. To our knowledge, this is the first
study to examine the impact of heparin withdrawal on
ischemic episodes detected by continuous ST segment
monitoring among the unstable angina/non-Q-wave MI
population in the treatment setting of concomitant use of
ASA. Theroux et al. (18) demonstrated early reactivation of
unstable angina and MI occurring within the first
96 h (clustered around 10 h) after UFH discontinuation in
those patients not receiving simultaneous aspirin therapy. In
our analysis even in the presence of ASA, rebound
ischemia occurred more frequently among patients with-
drawn from heparin as compared with enoxaparin. In
addition, the time to rebound ischemia was longer and the
frequency and duration of ischemic episodes was less among
patients withdrawn from enoxaparin therapy. This finding
is consistent with the known pharmacokinetic advantages of
LMWHs over UFH (19). The superiority of enoxaparin
may be explained by: 1) the higher antifactor Xa to
antifactor IIa ratio (3:1 vs. 1:1 with UFH), with relatively
greater inhibition of thrombin generation while maintaining
similar activity against thrombin inhibition, 2) stimulation
of more tissue factor pathway inhibitor release, leading
to greater inhibition of thrombin generation and activity,
3) less platelet activation and greater resistance to inhibition
by activated platelets, and 4) reduced release of
von Willebrand factor (19–21). The mean heart rate at the
onset of ischemia was not substantially different from the
heart rate preceding the ischemic episode in both treatment
Figure 4. Kaplan-Meier plot of 1-year event-free survival from death or
nonfatal myocardial (re)infarction among patients with ST segment shift
on baseline 12-lead ECG (solid lines): 1) with ST segment change
(ischemia) during continuous monitoring (heavy solid line, n 5 44) and 2)
without ischemia during continuous monitoring (light solid line, n 5 41)
and among patients without ST segment shift on baseline 12-lead ECG
(dashed lines): 1) with ischemia (heavy dashed line, n 5 43) and 2)
without ischemia (light dashed line, n 5 103).
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groups and 70% of ischemic episodes were associated with a
less than 10% increase in heart; this supports the concept
that ischemia was more likely due to a decrease in coronary
blood flow (e.g., recurrent thrombosis) than increased myo-
cardial oxygen demand (e.g., increased heart rate related to
physical activity).
Prognostic value of ST segment shift. The independent
value of ST segment shift on continuous monitoring in
predicting adverse outcomes at one year was particularly
evident among those patients who demonstrated ST shift
on the baseline 12-lead ECG and those who received UFH
as compared with enoxaparin. In patients without recurrent
ischemia, the risk of MI and death was relatively low and
similar among the treatment groups and those with or
without ST shift at baseline. On the other hand, patients
with recurrent ischemia during continuous monitoring,
particularly those with ST shift at baseline or treated with
heparin, exhibited a higher risk for adverse outcome. This
finding is similar to those of previous investigators utilizing
continuous 2-channel (22) or vector-derived 12-lead ECG
(23) ischemia monitoring or baseline troponin levels (24,25)
to identify retrospectively those patients with unstable
angina/non-Q-wave MI most likely to benefit from anti-
platelet (glycoprotein IIb/IIIa receptor antagonist plus
UFH 6 aspirin) (22–24) or antithrombotic therapy
(LMWH dalteparin plus aspirin vs. aspirin alone) (25).
Thus, simple 3-lead continuous ECG monitoring also
appears to be a useful noninvasive tool for further risk
stratification and selection of high-risk patients who may
require more potent antithrombotic therapy.
Conclusions. ST segment shift occurs frequently among
patients with unstable angina and non-Q-wave MI despite
antithrombotic therapy and is associated with worse one-
year prognosis. The LMWH enoxaparin is a more effective
antithrombotic treatment than UFH and leads to greater
prevention of rebound ischemia.
APPENDIX
Study Centers, Principal Investigators and Study Coor-
dinators Participating in the Canadian ST Segment
Monitoring Substudy:
York Central Hospital, Richmond Hill (E. Gangbar, L.
Willoughby); Humber Memorial Hospital, Weston (M.
Cheung, L. Yao, P. Girard); Centenary Health Center,
Scarborough (N. Singh, B. Bozek); St. Michael’s Hospital,
Toronto (S. Goodman, A. Langer, B. Nolf); Oshawa
General Hospital, Oshawa (R. Bhargava, N. Kachra); Mis-
sissauga Hospital, Mississauga (T. Rebane, H. Hink); Peel
Memorial Hospital, Brampton (M. Gupta, C. Kern);
Windsor Health Clinic, Windsor (A. Glanz, J. Fulop, A.
Schiller); Etobicoke General Hospital, Etobicoke (K.
Kwok, C. Kern); Oakville-Trafalgar Memorial Hospital,
Oakville (A. Zawadowski, R. Franks); Credit Valley Hos-
pital, Mississauga (H. Strauss, P. Anderson); Royal Victoria
Hospital, Barrie (B. Burke, R. Chomyc); Stamford Medical
Center, Niagara Falls (R. Tannous, D. Zaniol); North York
General Hospital, Willowdale (B. Lubelsky, D. Burge);
York-Finch General Hospital (T. Bhesania, D. Burge);
Bowmanville Memorial Hospital, Bowmanville (W.
Heslop, N. Kachra); Joseph-Brant Memorial Hospital,
Burlington (I. Darcel, P. Anderson); Curans Health Center,
Thunder Bay (C. Lai, K. Kwiatkowski) and York County
Hospital, Newmarket (A. Hess, M. Gaudet).
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